Partner Headlines - MDVN

  1. Medivation Voted Three Years in a Row Among Top Workplaces in ...

    GuruFocus
  2. UPDATE: Medivation, Astellas Report Enrollment of First Patients ...

    Benzinga
  3. New Enzalutamide Data in Triple-Negative Breast Cancer Presented ...

    Benzinga
  4. Stocks: A Soft Jump On Jobs Data; WhiteWave, Boeing, NXP Climb

    IBD
  5. Top Drugmaker Profits Mixed

    IBD
  6. Medivation, Jazz Q1 Reports Miss; Regeneron Beats

    IBD
  7. Four Hot Stocks You'll Want To Keep On Your Radar

    IBD
  8. Nasdaq, S&P 500 Hang Tough; Avago, Akorn Big Earnings Winners

    IBD
  9. Medivation Tops Q4 Views On Strong Xtandi Results

    IBD
  10. Stocks Mixed; United Therapeutics Jumps To New High

    IBD
  11. Market Edges Higher, Unfazed By Weak HP Results

    IBD
  12. Market's Resilience Is Noteworthy; More Breakouts Emerge

    IBD
  13. Earnings Scheduled For February 25, 2015

    Benzinga
  14. Stocks Show Small Losses; Merger Talk Lifts Discovery

    IBD
  15. Stocks Quietly Lower; Domino's, Medivation Break Out

    IBD
  16. Wedbush Weighs in on Medivation Following Phase II TERRAIN Study ...

    GuruFocus
  17. Valeant Agrees To Buy Dendreon's Provenge

    IBD
  18. Weekly CEO Sells Highlight: QAD Inc, Orbitz Worldwide Inc, Constellation ...

    GuruFocus
  19. Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically ...

    GuruFocus
  20. J&J Earnings Beat, But Sales, Guidance Miss Estimates

    IBD
  21. Eli Lilly Has 'Turned The Corner,' Upgraded

    IBD
  22. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  23. Barclays Analyst Sees Biotech FY15 EPS Growth Outstripping Market

    Benzinga
  24. William Blair's Top BioPharmaceutical Stock Picks for Q1 2015

    GuruFocus
  25. Newly Profitable Medivation Riding High On Drug Sales

    IBD
  26. Chip Stocks, Biotechs Lead Another Nasdaq Rally

    IBD
  27. Major Upgrades And Downgrades In Friday's Market Action

    Benzinga
  28. Medivation Hits High After Q3 Earnings Beat

    IBD
  29. Medivation Hits High After Q3 Earnings Beat

    IBD
  30. Medivation and Astellas Announce Phase 3 Study of Enzalutamide ...

    GuruFocus
  31. J&J Earnings Beat; Olysio Chatter Hits Gilead

    IBD
  32. Consider Medivation for Your Portfolio

    FoxBusiness
  33. Benzinga's Top Downgrades

    Benzinga
  34. Goldman Sachs Downgrades Medivation To Neutral, Shares Drop

    Benzinga
  35. These 3 Biotech Stocks Just Hit New Highs

    Benzinga
  36. Fast Money Halftime Report Final Trade From September 12

    Benzinga
  37. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD
  38. Stifel Raises Medivation Inc Price Target

    Benzinga
  39. Stocks Hitting 52-Week Highs

    Benzinga
  40. A Few Reasons Why Investors Should Consider Dendreon for Their ...

    GuruFocus
  41. Medivation Cancer Drug Fuels Beat, Swings To Profit

    IBD
  42. Benzinga's Volume Movers

    Benzinga
  43. Medivation Announces Change in Executive Management Team; Dawn ...

    Benzinga
  44. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  45. Aegis Capital Believes Seragon Deal Underscores Value In Medivation

    Benzinga
  46. UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer ...

    Benzinga
  47. Benzinga's Top Upgrades

    Benzinga
  48. US Stock Futures Flat Ahead Of International Trade Data

    Benzinga
  49. UPDATE: Canaccord Genuity Initiates Coverage on Medivation as ...

    Benzinga
  50. Morning Market Movers

    Benzinga
  51. Stocks To Watch For April 1, 2014

    Benzinga
  52. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, ...

    Benzinga
  53. UPDATE: Astellas Announces Marketing Approval in Japan for XTANDI® ...

    Benzinga
  54. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  55. Market Wrap For February 28: Markets Unable To Hold On To Gains

    Benzinga
  56. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  57. Benzinga's Top #PreMarket Losers

    Benzinga
  58. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts
  59. Mid-Afternoon Market Update: Fed Will Continue the Taper in February

    Benzinga
  60. Mid-Day Market Update: Yahoo! Slips After Q4 Results; RF Micro ...

    Benzinga
  61. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  62. Mid-Morning Market Update: Markets Open Lower; Dow Chemical Posts ...

    Benzinga
  63. Stocks Hitting 52-Week Highs

    Benzinga
  64. Benzinga's Top #PreMarket Gainers

    Benzinga
  65. Medivation and Astellas Announce Final Results From the Phase ...

    Benzinga
  66. UPDATE: Aegis Capital Reiterates on Medivation Following In-Line ...

    Benzinga
  67. Medivation, Astellas Announce Phase 3 PREVAIL Trial of Enzalutamide ...

    Benzinga
  68. Uh Oh: Is This Cancer Highflyer In Your Account?

    YCharts
  69. Worse-Than-Expected Xtandi Sales Hitting Shares of Medivation; ...

    Benzinga
  70. Medivation Elects Kathryn Falberg to Board of Directors

    Benzinga
  71. Medivation Bulls Load Up on Call Options

    SchaeffersResearch
  72. Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation

    Benzinga
  73. Medivation, Inc. (MDVN) President and CEO David Hung sells 1 ...

    GuruFocus
  74. Benzinga's Top Initiations

    Benzinga
  75. Celgene, Regeneron Pharmaceutical Lead Biomed Group

    IBD
  76. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  77. UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Medivation

    Benzinga
  78. Medivation Effects 2-for-1 Stock Split

    Benzinga
  79. Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

    Benzinga
  80. US FDA Approves XTANDI for Patients With Metastatic Castration-Resistant ...

    Benzinga
  81. Medivation Reports 2-for-1 Forward Split of Common Stock

    Benzinga
  82. Andreas Halvorsen Buys 2 Million Shares of Medivation

    GuruFocus
  83. Medivation Inc. (MDVN) President and CEO David Hung sells 25, ...

    GuruFocus
  84. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  85. Stocks Hitting 52-Week Highs

    Benzinga
  86. Health Care Sector Wrap

    FoxBusiness
  87. Four Winning Trades Based on Analyst Calls

    Benzinga
  88. Medivation Bull Looks to Cash In on Continued Rally

    SchaeffersResearch
  89. Analyst Upgrades: MDVN, SCHN, and STI

    SchaeffersResearch
  90. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  91. Citigroup Reiterates Buy Rating, $129 PT for Medivation

    Benzinga
  92. Medivation and Astellas Announce Enzalutamide Data

    Benzinga
  93. Crazy Action in Medivation After Negative StreetSweeper Post

    Benzinga
  94. Global Fears and Small Caps: How Much of an Impact?

    Benzinga
  95. Social Media Outlook for Tuesday 15 (DKS, MDVN, BBY, ACOM)

    Benzinga
  96. GlaxoSmithKline, Vertex Point To Biotech Strength

    IBD
  97. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  98. Will Johnson & Johnson Cure Cancer?

    Benzinga
  99. Options Players Show a Preference for Medivation Puts

    SchaeffersResearch
  100. Notable Put Options Activity in Medivation

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!